Date: 2015-10-01
Type of information: Product acquisition
Compound: Nimenrix®, Mencevax®
Company: Pfizer (USA - NY) GSK (UK)
Therapeutic area: Infectious diseases
Type agreement: product acquisition
Action mechanism: vaccine. Nimenrix® (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) is a single-dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine designed to protect against Neisseria meningitidis. It is indicated for all age groups above one year of age. Mencevax® (meningococcal polysaccharide serogroups A, C, Y and W-135 vaccine) is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers in countries where the disease is endemic or highly epidemic.
Disease: prevention of meningococcal disease
Details: * On October 1, 2015, Pfizer announced that it has completed the acquisition of GSK’s quadrivalent meningococcal ACWY vaccines Nimenrix® and Mencevax®. Launched three years ago, Nimenrix® is currently registered and approved for sale in 63 countries across the European Economic Area (EEA 30), Canada, Australia and Emerging Markets, with registrations under review in another 17 countries across Africa, Asia, Eastern Europe and the Middle East. Mencevax® is indicated for use across all age groups from 2 years of age, and is currently registered and approved in 78 countries across Africa, Asia, Australia, Europe, Latin America, Middle East and New Zealand.
Financial terms:
Latest news:
